Tada,

Thanks for the clarification. However, I still don't understand why you think that the Renal IND/trial approval would be such a catalyst for the share price. Based on the various trials to date, we know that RVX-208/apabetalone is at least safe enough for no red flags to arise other than the minor and transient liver transaminase elevation is a subset of patients. So the Renal IND/trial approval shouldn't come as too much of a surprise. It's not so much a matter of if the IND/trial will be approved but when. And this would just be the start of the trial, not the results of the trial.

Could you please elaborate on why you think "this could literally be the beginning of the launch into the stratosphere for our share price"

Thanks,

BDAZ